GLP-1 injections are utilized for medical weight loss by enhancing satiety and slowing digestion, effectively helping patients reduce calorie intake and manage their weight
Patients should report persistent injection site changes, unexplained neck masses, severe gastrointestinal symptoms, or signs of pancreatitis promptly for appropriate clinical assessment and management
By month 2, the vast majority of users (85%) report significant reductions in snacking and overall food intake
For additional information, please reference Provider Bulletin 48-07
However, absorption is still low and ingestion of a 14 mg tablet of semaglutide is required to achieve comparable plasma levels to those achieved with 1 mg of the s.c
European survey finds over three-quarters of adults with obesity have attempted to lose weight in the past year, but most have been unsuccessful